运动在肺高血压中的作用:从长椅到床边的证据
Ganesha Poojary1,2, Norman Morris3,4, Manjunath B Joshi2
1Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India.
Pulse (Basel, Switzerland)
|July 18, 2024
概括
运动通过增强细胞功能和运动能力来改善肺高血压 (PH) 患者的结果. 需要进行进一步的研究,以优化对这种衰弱状况的炼方案.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 运动生理学 运动生理学
背景情况:
- 肺高血压 (PH) 的特点是肺动脉高压和血管重塑,导致运动不耐受.
- 细胞和分子机制显著影响PH进展和生理反应.
- 在PH管理中,运动被认为对生理系统有积极的影响.
研究的目的:
- 审查运动在改善肺高血压 (PH) 功能中的作用.
- 突出导致运动不耐受和运动诱导的PH改善的细胞和分子途径.
- 讨论支持运动训练作为PH的辅助治疗的临床证据.
主要方法:
- 对PH中运动干预措施的临床前和临床研究的审查.
- 基于运动效益的细胞和分子机制的分析.
- 评估临床结果,包括运动能力和生活质量.
主要成果:
- 运动训练改善了内皮功能,减少了炎症和氧化应激,并增强了PH中的线粒体功能.
- 临床研究表明,通过运动干预,运动能力,血液动力学和生活质量显著改善.
- 运动可以增强骨肌肉功能,并对肺血管重塑产生积极影响.
结论:
- 运动是一种有前途的PH辅助疗法,补充药理疗法.
- 需要进一步的研究来优化炼方案,包括强度,持续时间和患者选择.
- 阐明潜在的机制将使个性化炼策略能够更好地管理PH.
更多相关视频
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
164
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
164
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
193
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
193
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
Exercise and Cardiovascular Response
771
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
771
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
143
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
143
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150


